Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Class A common stock, par value $0.00001 per share
-
Shares outstanding
-
111M
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
89.5M
-
Shares change
-
+2.15M
-
Total reported value, excl. options
-
$3.69B
-
Value change
-
+$73.6M
-
Put/Call ratio
-
0.48
-
Number of buys
-
108
-
Number of sells
-
-141
-
Price
-
$41.25
Significant Holders of 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) as of Q3 2023
308 filings reported holding TXG - 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share as of Q3 2023.
10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) has 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.5M shares
of 111M outstanding shares and own 80.44% of the company stock.
Largest 10 shareholders include FMR LLC (12.7M shares), VANGUARD GROUP INC (8.9M shares), BAILLIE GIFFORD & CO (8.34M shares), BlackRock Inc. (5.49M shares), MORGAN STANLEY (4.35M shares), SANDS CAPITAL MANAGEMENT, LLC (3.99M shares), BROWN CAPITAL MANAGEMENT LLC (3.08M shares), ARK Investment Management LLC (2.99M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.69M shares), and Invesco Ltd. (2.23M shares).
This table shows the top 249 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.